Q2 2024 Zydus Lifesciences Ltd Earnings Call Transcript
(technical difficulty)
For today's call we have Dr. Sharvil Patel Managing Director; Mr. Nitin Parekh, Chief Financial Officer; Mr. Arvind Bothra, Senior Vice President, Investor Relations; and Mr. Alok Garg Senior Vice President from the Managing Director's office. Now let me give you a broad overview of the developments during the quarter.
In terms of overall revenues, we registered stable growth of 9% during the quarter. Our Branded Formulations business in India grew in a single high digit after adjusting for impact of NLEM and partly affected by delay in the acute season. The U.S. Formulations business performed on expected lines, driven by a stable base business and supported by new introductions. Our Emerging Markets and Europe Formulations businesses continued growth momentum and delivered double-digit growth.
Our network of regulatory-compliant manufacturing facilities and a resilient supply chain serves as the backbone of our globally -- global business. We remain committed to extend our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
